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ABSTRACT 
CD4 T cells are crucial coordinators of protective immune responses against microbes and 
tumors. However, immune responses misdirected towards self-antigens are the hallmarks 
of autoimmune diseases. Regulatory T cells (Tregs) maintain peripheral immune 
tolerance, mainly by suppressing effector T cells. Unfortunately, immunosuppression by 
Tregs can also favor cancer. Regulating the susceptibility of T cells towards Treg-
meditated immunosuppression presents an exciting approach to reconcile between 
immune activation and tolerance in a disease-specific way. However, less is known about 
the regulation and mechanism of Treg-mediated suppression in target T cells. The work 
presented in this thesis is dedicated to unraveling the modulation of signaling cascades in 
T cells upon T cell receptor (TCR) stimulation and suppression by Tregs. 
By using unbiased phosphoproteomics, we have mapped the global phosphoproteome of 
T cells upon TCR stimulation and suppression by Tregs. Our data indicate that Tregs 
suppress T cells mainly by opposing activation-induced phosphorylation. We discovered 
that Tregs revert activation-induced phosphorylation of DEF6 at specific sites (T 595 / S 
597). Utilizing phospho-mutants, we discovered novel functions of these phosphorylations 
in disrupting the interaction of DEF6 with the IP3R and regulating T cell signaling via 
modulation of NFAT activation and transcriptional regulation of T cell cytokines. Upon 
further exploration of the phosphoproteomic candidate list, we observed similarly altered 
phospho-regulation of protein phosphatase 1, regulatory subunit 11 (PPP1R11) by Tregs. 
We revealed that silencing of PPP1R11 renders T cells resistant to Treg-mediation 
suppression. Our data indicates PPP1R11 to be a novel regulator of T cell activation and 
Treg-mediated suppression. In light of several reports on resistant T cells in multiple 
diseases, the phosphoproteomic mapping of suppressed T cells and the insights into novel 
roles of DEF6 and PPP1R11 from our study may aid in regulating the sensitivity of T cells 
towards immunosuppression by Tregs in cancer and autoimmune diseases.  
Besides phosphorylation of proteins, the subcellular localization of proteins is also an 
important regulatory mechanism of protein activity. Protein localization and activity is 
modulated by TCR stimulation and was shown for well-known TCR signaling proteins 
such as NFAT to be affected by Tregs as well. However, these mechanisms are not 
understood on a global level. Since there is no global data set available on subcellular 
protein localization and TCR stimulation-induced translocation in primary human T cells, 
as the first milestone in this field, we have performed a comprehensive mapping of the 
spatial proteome of T cells and TCR-induced subcellular protein translocation. 
Besides exploring the target T cell side, in this work we also studied novel methods to 
induce Tregs, which represents the “other side” of Treg-based immune therapies. We 
present a novel method of inducing iTregs by using supernatants from M2 macrophages. 
Our data demonstrate that M2 macrophages induce iTregs by binding and re-releasing 
TGF-β, which may be explored for Treg induction in situ in the future. 
Together, by presenting a global picture of T cell protein signaling yet with fine 
resolution, our work provides new mechanisms and data sets to revisit the role of T cells in 
therapy, especially in the context of T cell suppression by Tregs. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
A competent immune system is essentially a coordinated interplay between activatory and 
tolerogenic waves to ensure adequate responsiveness and protection against harmful antigens 
and tumors while also maintaining non-responsiveness to self and innocuous antigens. 
Controlling these accelerations and brakes of the immune system serve as the basis of 
devising immunotherapeutic interventions against malignancies. Broadly speaking, 
immunological defense in vertebrates comprises of 2 main legions: innate (natural) immunity 
conducting the early reactions and adaptive immunity conducting the later steps which are 
based on cues acquired from previous exposure to antigens (Ags). The immunological battle 
is fought on several fronts; B and T lymphocytes (T cells) are crucial mediators of humoral 
and cell mediated-adaptive immune responses, respectively. Depending on the expression of 
the coreceptor, T cells are aptly divided into helper CD4+ T cells and cytotoxic CD8+ T cells. 
We have come far since J. Miller being publicly reminded that B and T were the first and last 
letters of “bullshit” when he proposed the existence of these two subsets of lymphocytes in a 
scientific conference in 1968 (Miller, 1999) till present day when CD4 and CD8 T cell counts 
are routinely used even in basic clinical tests. With several chemo- and immunotherapeutic 
treatment against cancers, infections, autoimmune diseases, allergies and transplant rejections 
targeting T cells, both in pipelines and clinics along with the recently approved CAR T cell 
therapies, it is truly an exciting time to work with T cells.  
1.2 CD4 T CELLS: DEVELOPMENT AND TOLERANCE 
T cells, like other blood cells, originate from the hematopoietic progenitor cells in bone 
marrow. Unlike other hematopoietic cells, T cells mature in the thymus (Shortman and Wu, 
1996). Immature thymocytes are CD4-CD8-, and are hence termed double negative (DN). 
DN thymocytes proliferate and mature in thymus and eventually acquire a double positive 
state (CD4+CD8+) (DP) (von Boehmer et al., 1988). During the process of maturation, they 
acquire mature T cell receptor (TCR) proteins (αβ or γδ) determining their specificity and 
selectivity to detect the vast array of Ags even before they have been encountered. DP 
thymocytes which recognize the self Ag:MHC complex expressed by the cortical epithelial 
cell with low affinity undergo positive selection and mature into functional CD4 or CD8 T 
cells depending on their association with MHC class II or MHC class I respectively 
(Mizuochi et al., 1992). Simultaneously, over 90% of DP thymocytes with none or too low 
affinity to the Ag:MHC complex undergo apoptosis in lack of survival cues by the process 
aptly named “death by neglect.”. Random combination of TCR gene segments to engineer 
over 109 unique TCRs (Lythe et al., 2016) using a limited number of TCR genes is a genetic 
masterstroke but also gives rise to TCRs with strong affinity to self-Ags (Feeney et al., 1994). 
The generation of these potentially autoimmune T cells is averted by the process of “central 
tolerance”. These DP T cells with too high affinity to self Ag:MHC complex on medullary 
thymic epithelial cells are negatively selected for “clonal deletion” (Shortman and Wu, 1996). 
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Further, immature T cells which exhibit affinity stronger than the positively selected 
population described above, but weaker than the clonally deleted population are rescued and 
skewed to differentiate as regulatory T cells (Tregs) by the process of “clonal diversion” 
(Klein et al., 2019). 
Although about 98 % of cells do not survive central tolerance mechanisms in the thymus, 
some autoreactive T cells still evade to systemic circulation which are then to be controlled 
by various mechanisms of peripheral tolerance, as described here. TCR stimulated T cells 
lacking co-stimulation undergo functional inactivation called “anergy”. Repeated activation 
of T cells with persistent Ags leads to apoptosis via the process termed “activation-induced 
cell death” (Green et al., 2003). Autoreactive T cells are further controlled by regulatory T 
cells (Tregs) in the periphery. 
1.3 CD4 T HELPER CELLS AND SUBSETS 
CD4 T cells are the most abundant lymphocytes in peripheral blood which initiate and sustain 
diverse immunological responses mainly by regulating other immune cells, hence aptly 
named helper T cells. Depending on the immune micro milieu and the type of antigenic 
stimulation, CD4 T cells have tendencies to polarize into several distinct subsets. These 
subsets have specialized immunological functions which are mainly mediated by the 
expression of signature cytokines and have unique genetic signatures mainly guided by their 
lineage-defining “master” transcription factors. Further, preferred transcription factors of the 
signal transducer and activator of transcription (STAT) family are also activated upon 
cytokine receptor stimulation of the T cells, which then also regulates the cytokine profile, 
upstream and in addition to the respective master transcription factors. Figure 1 depicts a 
simplified and unidirectional map of CD4 T cell differentiation and functions. While it is well 
understood that plasticity exists between the subtypes and functions (O’Shea and Paul, 2010; 
Oestreich and Weinmann, 2012), CD4 T cells can be divided into two broad functional 
categories: immunogenic effector T cells (Th1, Th2, Th17, and Tfh) and immunosuppressive 
Tregs as depicted in Figure 1 and described further.  
1.3.1 Th1 and Th2 cells 
Th1 and Th2 cells were the first subtypes of effector CD4 T cells that were discovered. The 
polarization of Th1 cells is mainly mediated by IL-12 and IFN-γ secreted by innate immune 
cells, NK cells, and T cells. Signaling mediated by STAT4 and the master transcription factor 
T-bet dictate the immunological function of Th1 cells via secretion of IL-2 and IFN-γ as their 
hallmark cytokines. Th1 cells activate and recruit macrophages and cytotoxic CD8 T cells to 
clear out cells infected with intracellular pathogens like bacteria and viruses. Similarly, Th2 
cells are generated in the presence of IL-2 and IL-4 which drives the STAT6 and 
subsequently GATA3-mediated secretion of Th2 cytokine profile consisting of IL-4, IL-5, 
and IL-13. Th2 cells contribute to immunity against extracellular pathogens like parasitic 
helminths and stimulate repair of tissue damage (Romagnani, 1991, 2014; Walker and 
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McKenzie, 2018). Anomalies in Th1 and Th2 cells contribute to autoimmunity and allergies 
respectively. 
1.3.2 Th17 and Tfh cells 
Th17 and Tfh are more recent additions to the CD4 T cell subsets, and further subsets have 
been proposed (Th3, Th9, and Th22) that are not discussed here. The polarization of Th17 
cells is regulated majorly by IL-6 and TGF-β which drive the STAT3 and subsequently 
RORγ-mediated secretion of IL-17A, IL-17F, and IL-22 (Romagnani, 2014), although other 
cytokine combinations have also been described to induce Th17 cells. Th17 cells are 
involved in clearing extracellular microbes like fungi and bacteria at the mucosal surfaces. 
Tfh cells are specialized T cell subsets, mainly present in the follicles of lymph nodes where 
they contribute to B cell maturation and activation. Human Tfh cells can be generated in the 
presence of IL-6, IL-21 and TGF-β which guides the STAT3 and BCL-6 mediated 
expression of IL-21 while they also produce other Th cytokines (Crotty, 2014). Generally, 
the differentiation factors and cytokines driving the above-described subsets are here noted in 
a simplified way, since depending on the stimulation conditions and other factors in the 
medium, different cytokines may mediate the effects. Further, species differences exist, most 
notably also between human T cells and commonly used murine T cells. 
 
Figure 1: CD4 T helper cell subsets. Naïve CD4 T cells (grey) can differentiate into immunogenic 
effector T cells (Th1, Th2, Th17, and Tfh) (right side) and immunosuppressive Tregs (left side) 
(different colors) in the presence of TCR stimulation and CD28 co-stimulation. Cytokines that can 
drive the polarization along with master transcription factors and STAT molecules which are 
expressed by individual subsets are also mentioned. Additionally, major cytokines produced upon 
differentiation and primary immune targets of each subtype are also depicted. 
1.4 REGULATORY T CELLS 
Tregs are tolerogenic subsets of CD4+ T cells which mediate peripheral self-tolerance by 
suppression of effector T cells and other immune cells.   
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1.4.1 Tregs, a historical perspective 
The history of Tregs dates back to the early 1970s after the discovery of thymus-derived cells 
exhibiting suppressive effects on other immune cells (Gershon et al., 1972) and preventing 
thymectomy-induced autoimmunity on adoptive transfer to the recipient mice (Kojima et al., 
1976). However, the next two decades witnessed a dramatic decline in research interest in the 
field for these “suppressor cells”, mainly because of lack of characteristic molecular markers 
and partly because of findings negating the proposed mechanism of suppression being 
mediated by soluble factors (Shevach, 2011). The whole field showed some signs of 
rejuvenation after the discovery of CD25 (IL-2 receptor α chain) as a surface marker for 
Tregs in mice (Sakaguchi et al., 1995) and finally in humans (Baecher-Allan et al., 2001; 
Stephens et al., 2001). It was after the discovery of Foxp3 as a lineage-defining transcription 
factor for Tregs (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003) that the field of 
Tregs started its “renaissance” and started to attract tremendous interest from the 
immunological community. Now, Tregs are established as the primary mediator of peripheral 
tolerance crucial for the aversion of autoimmune disease, allergies, transplant rejection and 
graft versus host disease (GvHD). Several therapies involving Tregs are in experimental 
phase and clinical trials in Type 1 Diabetes, Inflammatory bowel diseases (IBD) and organ 
transplantation (Duggleby et al., 2018). 
1.4.2 Phenotype of Tregs 
Phenotypically, Tregs are broadly defined as CD4+, CD25++, Foxp3+ suppressor cells 
(Sakaguchi, 2011). Although the expression of CD25 (IL-2 receptor α chain) is limited to 
Tregs in naïve mice, activated T cells are also known to transiently express medium levels of 
CD25 (Baecher-Allan et al., 2001), hence Tregs in humans may rather be characterized by 
high expression of CD25. Moreover, Foxp3 is widely accepted as the lineage-defining 
“master” transcription factor for Tregs. In fact, it is the mutation in Foxp3 which mediates 
systemic autoimmune disease both in mice (scurfy) and humans (IPEX syndrome) and hence 
primarily established the importance of Tregs in autoimmunity. In contrast to murine T cells, 
human conventional T cells have been reported to express medium levels of Foxp3 upon 
activation (Pillai et al., 2007). Despite being the most characteristic marker for Tregs to date, 
expression of Foxp3 cannot be an absolutely specific marker for Tregs and neither can CD25. 
In light of such ambiguity, the methylation pattern in the Treg-specific demethylated region 
(TSDR) in the Foxp3 locus and lack of or low expression of CD127 (IL-7Rα ) can be used to 
distinguish Tregs from activated T cells (Huehn et al., 2009; Liu et al., 2006).  
Naturally occurring Tregs (nTregs) consist of thymus-derived Tregs (tTregs) and 
peripherally-derived Tregs (pTregs), whereas in vitro generated Tregs are termed as iTregs 
(Rudensky et al., 2013). For all further discussions, the term “Treg” will indicate nTregs. 
Apart from the formal location-based classification of Tregs, they may also be classified 
according to the expression of FOXP3 / CD25 and CD45RA (a marker of naïve T cells) into 
CD45RA+FOXP3 low resting Tregs and CD45RA-FOXP3+ activated Tregs (Miyara et al., 
2009). Furthermore, specific suppressors of Tfh; follicular Tregs expressing low or no CD25 
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and IL-10 producing Type 1 regulatory T cells which have transient or no FOXP3 expression 
have also been widely considered as functional classes of Tregs (Groux et al., 1997; Wing et 
al., 2018). Such classifications reflect uncovered knowledge about Treg biology. 
1.4.3 Generation of Tregs 
As mentioned earlier, thymic Tregs are differentiated from immature thymocytes in the 
thymus by the process of “clonal diversion”. Strong TCR signal by self Ag:MHC along with 
CD28 co-stimulation drive the expression of CD25 which enables the cellular response 
towards IL-2 signaling and subsequent expression of FOXP3 mediated by STAT5 and other 
factors (Burchill et al., 2008).  
Although the majority of Tregs are estimated to be constituted of tTregs (70-80% in both 
mice and men) as defined by the expression of IKZF2 (Helios) and reviewed in (Shevach and 
Thornton, 2014), some portion of nTregs also consists of extrathymically derived pTregs. 
While Helios is used to differentiate tTregs and pTregs, it is not an absolute marker, and 
instead, Neuropilin-1 is recommended to be a more suitable marker of tTregs, at least in mice 
(Yadav et al., 2012). 
 pTregs are either differentiated from naïve T cells or may be generated by conversion from 
other subsets of T helper cells in the periphery. The generation of pTregs is primarily shaped 
by IL-2 and TGF-β. Furthermore, vitamin A metabolite all-trans retinoic acid (ATRA) and 
commensal microbiota-derived short chain-fatty acids, mainly butyrate have also shown to 
favor the induction of pTregs in the gut region. The mediators of pTreg generation have not 
been fully understood and are also reported to be tissue-dependent and shaped by other 
immune cells like macrophages and DCs (Arpaia et al., 2013; Schmitt and Williams, 2013).  
In vitro generation of iTregs from naïve T cells has been an excellent platform to understand 
the development of pTregs. Protocols to generate iTregs have mainly been based on 
mimicking the in vivo regulators of pTreg generation like IL-2 and TGF-β, and recent works 
have also suggested the suitability of using molecules such as ATRA, butyrate and the mTOR 
inhibitor Rapamycin (Lu et al., 2014; Schmidt et al., 2016; Schmitt and Williams, 2013). 
1.5 TREG-MEDIATED SUPPRESSION OF T CELLS 
CD4+CD25- conventional T cells (here called T cells or Tcons), being the most abundant cell 
type among the lymphocytes, are crucial targets for immunosuppression by Tregs to maintain 
peripheral tolerance. Tregs employ myriads of suppression mechanisms presumably 
depending on the cytokine micro milieu and site of immune reaction as well as type and 
activation status of target cells and Tregs themselves to control the effector cytokine 
production and proliferation of T cells, as illustrated in Figure 2 (Schmidt et al., 2012). 
Understanding the individual mechanisms and their relevance in specific disease settings may 
be helpful to devise effective and suitable Treg-mediated therapies. The major mechanisms of 
suppression are described below. 
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1.5.1 Indirect suppression by modulation of APC function 
Tregs have been well documented to downregulate the stimulatory capacity of antigen 
presenting cells (APCs) hence contributing to the suppression of T cells indirectly. Cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) has been shown to capture its ligands CD80 / 
86 by trans endocytosis (Qureshi et al., 2011; Wing et al., 2008). Murine Tregs deficient in 
CTLA-4 have been shown to be less suppressive mainly due to reduced potency to 
downregulate CD80 / 86 on APCs. Strikingly, Treg-specific deletion of CTLA-4 resulted in 
severe lymphoproliferative diseases (Wing et al., 2008). Competitive inhibition of co-
stimulatory signals to CD28 in T cells has also been partly attributed to downregulation of 
CD80 / 86 in murine dendritic cells (DCs) by Lymphocyte function-associated antigen 1 
(LFA-1) from human Tregs (Tran et al., 2009). Tregs have also been reported to stimulate 
expression of tryptophan metabolizing enzyme, indoleamine 2,3-dioxygenase (IDO) in APCs 
via CTLA-4-dependent signaling to promote starvation and direct cell cycle arrest (Fallarino 
et al., 2006). Additionally, Tregs also recruit surface molecules like cluster of differentiation 
40 (CD40), neuropilin-1, Lymphocyte-activation gene 3 (LAG-3) and the antigen-
presentation attenuator A20 to downregulate the antigen (Ag) stimulatory capacity of DCs 
(Schmidt et al., 2012). Further, one recent study has also shown Tregs to hamper antigen 
presentation by capturing the MHC complex from APCs (Akkaya et al., 2019). 
1.5.2 Suppression by secretion of soluble molecules 
Tregs have been shown to produce various immunosuppressive cytokines like IL-10, TGF-β, 
and IL-35 for suppression of T cells. The importance and redundancy of these cytokines for 
Treg-mediated suppression of T cells seem to differ depending on the disease model, species 
and in vitro setup (Schmidt et al., 2012).  
Murine TGF-β has been shown to confer Treg-mediated suppression in vitro (Nakamura et 
al., 2004) and has also been shown to be crucial for preventing colitis (Read et al., 2000). 
Conversely, other groups had contradictory findings with reports of TGF-β knock out (KO) 
Tregs still being suppressive in vitro (Read et al., 2000). Furthermore, TGF-β plays a positive 
role in the generation of iTregs (Marie et al., 2005). Similarly, the importance of IL-10 has 
also been shown in several disease models like the experimental autoimmune 
encephalomyelitis and most prominently colitis (Asseman et al., 1999; McGeachy and 
Anderton, 2005).  
Studies have shown IL-35 to be important in Treg-mediated suppression of T cells in murine 
models; however human Tregs do not express IL-35 (Bardel et al., 2008). 
Tregs produce other repressive molecules like cyclic adenosine monophosphate (cAMP) 
(Bopp et al., 2007) and adenosine for direct or APC-mediated suppression of T cells 
(Borsellino et al., 2007). Particularly, cAMP seems to be more important for direct Treg-
mediated suppression of T cells. Treg-mediated suppression of IL-2 expression in T cells was 
initially suggested to act by the induction of inducible cAMP early repressor (ICER), which is 
a transcriptional repressor (Bodor et al., 2007). While ICER has a role in cytokine gene 
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expression, recent studies found ICER to be dispensable, and instead showed cAMP to act by 
promoting exchange protein directly activated by cAMP (EPAC) (Vang et al., 2013). Further 
Tregs have also been reported to utilize granzyme / perforin-mediated apoptosis induction in 
T cells (Grossman et al., 2004). 
1.5.3 Suppression by IL-2 consumption 
Tregs have been shown to induce IL-2 deprivation for T cells by consumption of IL-2 (an 
important growth factor for T cell proliferation) via IL-2R containing CD25 (IL-2R α chain) 
due to its high affinity for IL-2. Although shown to be important in an IBD model (Pandiyan 
et al., 2007), the resultant net effects on target T cells have been unclear. Tregs have also 
been shown to outcompete naïve T cells for IL-2 and utilize it for the induction of IL-10 
production (Barthlott et al., 2005).  
 
 
 
 
 
 
 
 
 
Adapted from Schmidt et al. 2012 Front. Immunol. 
Figure 2: Mechanisms of Treg-mediated suppression of T cells. Tregs regulate T cells by several 
immunosuppressive mechanisms illustrated in separate colors. Tregs can suppress T cells indirectly by 
modulating APCs. Tregs also directly suppress T cells by secretion of inhibitory cytokines and 
suppressive molecules. Furthermore, Tregs also suppress T cells by competing for IL-2 and apoptosis 
induction. Additionally, Tregs can rapidly suppress TCR-induced calcium-mediated signaling 
pathways in a contact-dependent manner. 
1.5.4 Contact-dependent suppression: Does it exist? 
While Treg-mediated suppression of T cells is mainly visualized within the boundaries of 
mechanisms mentioned above (acting via APCs and secretion of soluble factors), the 
relevance of direct suppression of T cells by Tregs is not widely accepted. This is in part 
because of lack of detailed knowledge of molecular pathways mediating this contact-
dependent suppression and evidences proving its in vivo relevance and occurrence. However, 
multiple in vitro studies have conclusively shown that Tregs can directly suppress 
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proliferation and / or activation of T cells in a contact-dependent manner without mediation 
by APCs or soluble factors in mice and humans (Ermann et al., 2001; Hagness et al., 2012; 
Huang et al., 2012; Oberle et al., 2007a; Thornton and Shevach, 1998). While earlier 
microscopic studies in intact explanted or intravital lymph nodes concluded that stable 
contact does not occur in vivo between Treg and T cells (Mempel et al., 2006; Tang and 
Krummel, 2006), a recent breakthrough study reported that Tregs stably contact T cells at the 
site of inflammation in murine non-lymphoid target tissues (Miska et al., 2014). In this study 
of murine pancreatic islet graft transplantation model, the stable contact between Tregs and T 
cells occurred both with and without mediation by APCs with only a minor role for CTLA-4 
(Miska et al., 2014). Furthermore, another imaging study has reconfirmed the direct 
interaction between endogenous Tregs and adoptively transplanted T cells in murine lymph 
nodes in a CTLA-4-dependent manner (Matheu et al., 2015). Further works are required to 
understand the in vivo significance and mechanism of direct suppression of T cells by Tregs. 
1.6 T CELL RECEPTOR SIGNALING AND ROLE OF PHOSPHORYLATIONS 
TCR signaling is essential for proliferation and cytokine secretion of T cells (Guy et al., 
2013). T cell activation requires recognition of Ag:MHC complex by TCR (Signal I), co-
stimulation via binding of CD80 / 86 to CD28 (Signal II) and finally signaling via cytokines 
(Signal III) (Corthay, 2006). TCR signaling induces the activation of three core transcription 
factors in T cells, which control cytokine transcription and decide cell fate. The central 
transcription factors include nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB), nuclear factor of activated T cells (NFAT), and activator protein 1 (AP-1).  
Ligation of the TCR complex with Ag:MHC complex initiates TCR signaling to result in 
activation of two Src kinases, CD3-associated Fyn kinase (via dephosphorylation by Tyrosine 
(Tyr) (Y) phosphatase CD45) and CD4-associated Lck kinase. Fyn-mediated phosphorylation 
of ITAMs in the cytoplasmic ζ chain of the CD3 receptor induces subcellular translocation of 
inactive cytosolic zeta-chain-associated protein kinase 70 (ZAP-70) to membrane-bound 
immunoreceptor tyrosine-based activation motif (ITAMs) of CD3, where ZAP-70 is further 
activated upon phosphorylation by Lck. ZAP-70, in turn, phosphorylates and activates linker 
for activation of T cells (LAT), which serves as an important branching point for further 
downstream signaling. Phosphorylation of Y132 on LAT recruits phospholipase Cγ1 
(PLCγ1) to induce calcium-dependent NFAT and NF-κB or RAS-MAPK pathways, which is 
primarily considered calcium independent. Phosphorylation of Y171, Y191, and Y226 on 
LAT activate guanine nucleotide exchange factor, SOS and SH2 domain-containing 
leukocyte protein of 76 kDa (SLP-76), which in turn regulate essential GTPases like Ras, 
Rac, and Rho and subsequently activate mitogen-activated protein (MAP) kinases like p38, 
JNK, and ERK1/2. The action of these kinases activates the AP-1 pathway by dimerization of 
c-Jun and Fos (to form the AP-1 transcription factor) upon translocation into the nucleus. 
Membrane recruitment and activation of PLCγ1 by LAT is mediated by activation of adaptor 
protein SLP-76 and IL2 inducible T cell kinase (Itk). PLCγ1 enzymatically cleaves 
phosphatidylinositol 4,5-bisphosphate (PIP2) generating the second messengers, 
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diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 is crucial for mediating 
calcium influx into the cytoplasm mainly by regulating Ca2+ gates of the endoplasmic 
reticulum (ER) by binding to IP3 receptor (IP3R). The resulting decrease in the ER Ca2+ levels 
activates stromal interaction molecules 1 and 2 (STIM 1 and 2) which then regulate the 
opening of Ca2+ channel in the plasma membrane composed of Calcium Release-Activated 
Calcium Modulator 1 and 2 (Orai1&2), resulting in store-operated Ca2+ entry (SOCE). 
Signaling induced by DAG and IP3 consequently activates NF-κB and NFAT respectively by 
unmasking nuclear-localizing sequences in the targets which mediates nuclear translocation 
of the activated NFAT and NF-κB from the cytosol (Prole and Taylor, 2019; Smith-Garvin 
and Koretzky, 2009; Vaeth and Feske, 2018; Zhang and Dong, 2005).  
1.7 TREG-MEDIATED SUPPRESSION OF PROLIFERATION VERSUS 
CYTOKINE EXPRESSION 
Broadly speaking, suppression of proliferation is considered a necessary condition for Treg-
mediated suppression of T cells, while suppression of activation-induced cytokines is usually 
considered as an intermediate step to install suppression of proliferation. However, it has 
been shown that cytokine expression can be independent of proliferation, since distinct TCR 
signaling pathways drive proliferation and cytokine secretion (Guy et al., 2013). Further, T 
cells have been shown to proliferate even when major components of TCR signaling and 
subsequently cytokine expression are disturbed (Oh-Hora et al., 2008). Even Tregs have been 
reported to suppress the expression of certain cytokines without affecting proliferation in 
CD4 T cells (Sojka and Fowell, 2011) and similarly, suppressing effector activity without 
affecting proliferation in CD8 CTLs (Mempel et al., 2006). Work by Schmidt et al. has also 
indicated that depending on the time point after the onset of suppression, Tregs can suppress 
cytokine secretion and proliferation independently (Schmidt et al., 2011). While suppression 
of cytokine expression and proliferation have been mostly dependent for the APC-mediated 
effect of Treg on T cell priming, suppressing the production of inflammatory cytokines might 
be more crucial in the inflamed tissues, at least in the early phase. 
1.8 RAPID SUPPRESSION OF TCR SIGNALING IN T CELLS BY TREGS 
Deciphering the details of rapid and early suppression by Tregs could enable the discovery of 
upstream mediators of suppression. It might be feasible to manipulate the machinery of Treg-
mediated suppression more effectively and specifically by targeting these upstream 
molecules.  
Initial studies in mice have characterized the dynamics for Treg-mediated suppression of IL-2 
expression in T cells, ranging from 6 to 15 hours (Sojka et al., 2005; Thornton and Shevach, 
1998). Oberle et al. demonstrated that human Tregs suppress cytokine transcription even 
more rapidly, within 1 to 3 hours in T cells independently of IL-2 consumption or secretion of 
soluble molecules (Oberle et al., 2007a). Using stronger TCR activation to enable an earlier 
robust read-out of cytokine expression, Schmidt et al. showed that the suppression of 
cytokines occurred as early at 30 minutes when pre-activated Tregs were used. The study 
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showed that Tregs rapidly suppress calcium and calcium-dependent NF-κB and NFAT 
pathways while the AP-1 pathway was primarily unaffected in T cells as depicted in Figure 2. 
Surprisingly, suppression was not mediated by known modification of proximal events of 
TCR signaling like ZAP-70, PLC-γ1, IP3 levels, or PKCθ phosphorylation. Additionally, this 
contact-dependent suppression was shown to occur both in the presence and absence of APCs 
and was independent of CTLA-4. More importantly, the hallmark of this study was the 
finding that Τregs suppress T cells by inhibition of TCR-induced depletion of the intracellular 
calcium stores and hence preventing the activation of NF-κB and NFAT1, which could be 
visualized as early as 5 minutes after activation (Schmidt et al., 2011).  
In a study on multiple sclerosis patients, Schwarz and colleagues have also demonstrated that 
Tregs fail to suppress calcium signaling but do not disrupt NFAT2 nuclear translocation in T 
cells (Schwarz et al., 2013). Further, Huang and Fowell claimed that Tregs selectively 
attenuate specific TCR signaling pathways to induce suppression. They have demonstrated 
that murine Tregs attenuate NF-κB signaling in T cells after 6 hours of activation in a setting 
independent of APC-activity. However, they observed sustained expression of NFAT1 and 
NFAT2 in suppressed cells (Huang et al., 2012). While studies mentioned above present 
NFAT as an activatory molecule for T cells especially within early time points, several 
studies claim NFAT1 to exert suppressive effects on T cells at later time points (Bopp et al., 
2005; Chellappa et al., 2015; Shin et al., 2014). This would be well in accordance with the 
dual role of NFAT mediating activation, but also the state of unresponsiveness (anergy) in T 
cells in the absence of costimulation (Macian et al., 2002). A recent work by Aandahl and 
colleagues suggested that human Tregs pre-activated for a prolonged time (48 hours) were 
able to suppress TCR-proximal signaling molecules as well as NF-κB and AP-1 upon 48 
hours of coculture and activation (Chellappa et al., 2015). Taken together, these studies hint 
at the possibility of multiple mechanisms mediating rapid suppression of T cells. While the 
NF-κB pathway appears to be consistently attenuated by Tregs across several studies, the role 
of NFAT in suppressed T cells may be dependent on activation time points, Treg pre-
activation, NFAT isoforms, and experimental setups. Additionally, a growing amount of 
recent works have reported impaired signaling in TCR pathways mainly involving Akt-
MAPK-AP-1 pathway to give rise to T cells resistant towards suppression by Tregs. Hence 
the importance of understanding the details of Treg-mediated signaling in T cells is even 
more evident.  
1.9 RESISTANCE AGAINST TREGS (VIVA LA REVOLUCIÓN) 
Presently, most of the research into Treg-mediated therapies either in experimental phase or 
clinical trials are mainly focused on regulating or strengthening the suppressive capacity of 
effector Tregs. Since the efficacy of treatment ultimately depends on the effect these Tregs 
have on the target cells, there can be untapped potential in modulating the susceptibility of the 
target T cells as well. Further, an increasing number of evidence in multiple autoimmune 
diseases shows that Tregs fail to suppress T cells partly because of resistance-induction in T 
cells (Buckner, 2010; Mercadante and Lorenz, 2016; Walker, 2009). These resistant T cells 
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serve as “red flags” and potential hurdles for therapies targeting T cells and Tregs. Less is 
known about the exact mechanisms of resistance. Studies report that T helper cell subsets 
vary in their susceptibility to Tregs. Th17 and Th2 cells along the diseases modulated by 
respective Th subsets have been shown to be more resistant to Tregs than Th1 cells (Cosmi et 
al., 2004; Stummvoll et al., 2008; Taams et al., 2007). T cell resistance has been associated 
with several cell-extrinsic factors, mainly impaired cytokine micro milieu involving the 
expression of TNF-α (Valencia et al., 2006; Wehrens et al., 2013), IL-4 (Pace et al., 2005; 
Pillemer et al., 2009), IL-6 (Schneider et al., 2013) and IL-15 (Ben Ahmed et al., 2009) in 
both experimental and clinical settings. The knowledge is even sparser regarding the cell-
intrinsic causes of resistance in T cells partly because the understanding of signaling events in 
the T cell upon suppression by Tregs is severely limited to canonical molecules and yet 
incomplete. Deregulation of SMAD7 (Fantini et al., 2009), CD28 (Thewissen et al., 2007), 
TRAF6 (King et al., 2006) and phosphatase SHP1 signaling (Mercadante and Lorenz, 2017), 
ultimately affecting the Akt-MAPK pathway, have been linked as some cell-intrinsic causes 
of resistance so far. There is a pronounced need for unbiased global studies to elucidate the 
molecular events initiated in T cells upon Treg-mediated suppression to fill the knowledge 
gap and resolve the potential issues arising from T cell resistance. 
1.10 PHOSPHOPROTEOMIC STUDIES IN T CELLS (TRADING THE TORCH 
FOR THE FLOODLIGHT) 
TCR signaling is largely mediated by phosphorylations, which is apparent by the 
involvement of multiple kinases and phosphatases, as described earlier. It is feasible that 
Tregs suppress T cells by regulating these already known or even unknown phosphorylations 
as shown for Treg-mediated regulation of some key phosphorylations of TCR signaling 
molecules (Chellappa et al., 2015; Huang et al., 2012; Schmidt et al., 2011). Hence the global 
mapping of the phosphoproteome of T cells upon suppression by Tregs might elucidate 
comprehensive mechanisms of Treg-mediated suppression of T cells. Since post translational 
modifications (PTMs) like phosphorylations can occur within seconds, mapping the 
phosphoproteome is even more suitable to study the mechanism of rapid suppression by 
Tregs which can occur as soon as 30 minutes of contact between Tregs and T cells and is then 
acting immediately after TCR stimulation, as soon as TCR signaling such as calcium influx 
becomes detectable (Schmidt et al., 2011).   
In eukaryotes, protein phosphorylations mainly occur on serine (Ser; S), threonine (Thr; T) 
and tyrosine (Tyr; Y) residues and mediate multiple signal transduction pathways. Besides 
these well-known substrates, phosphorylation can also occur on histidine, lysine, and arginine 
residues (Hunter, 2012). Although these additional phosphorylations might have some 
biological importance, their abundance is still debated and they are currently understudied 
(Fuhs and Hunter, 2017). Phosphorylation is mediated by the action of kinases and 
phosphatases which add and remove phosphate group to and from target proteins, 
respectively. 518 protein kinases and 189 protein phosphatases are identified in humans till 
date (Chen et al., 2017; Manning et al., 2002). Their importance in regulating biological 
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pathways are reflected by the observations that over 30% of proteins encoded by the human 
genome occur in a phosphorylated state (Cohen, 2002) and drugs targeting kinases are among 
the fastest growing drug family in recent years (Santos et al., 2016). Understanding the 
potential roles of kinases and phosphatases in mediating the phosphorylation-dependent 
effect of Tregs on TCR signaling in T cells could have significant potential for basic research 
as well as clinical application. 
Despite recent advancements in mass spectrometry (MS), limited attempts have been 
successful in mapping the global phosphoproteome and subcellular proteome of CD4 T cells 
in resting state and upon TCR activation. Few attempts at global profiling of TCR-induced T 
cell proteome are based on Jurkat T cell lines, not primary cells (Chylek et al., 2014; Nguyen 
et al., 2015a). The recently updated Lymphos 2.0 database provides comprehensive coverage 
of activation-induced changes in the phosphoproteome of human primary CD3+ T cells 
(Nguyen et al., 2015b). Further publications have also surfaced in profiling the 
phosphoproteome of murine CD8+ T cells (Navarro et al., 2011). In light of the central 
contribution of CD4+ T cells in immunity, in particular autoimmune diseases and several T 
cell-based immunotherapeutic approaches, there is a need of unbiased global profiling of 
TCR-induced changes in human CD4+ T cells. Impressive works have been accomplished in 
mapping the phosphoproteome of murine CD4+ T cells (Tan et al., 2017) and murine Tregs 
(van Ham et al., 2017) in recent years.  
Lacking any global study on the direct effect of Tregs on T cells, most knowledge is based on 
targeted studies of selected canonical molecules. Although these targeted studies have 
installed a backbone for understanding the signaling in suppressed cells, they are limited to 
the discovery of known and canonical molecules (Chellappa et al., 2015; Schmidt et al., 
2011; Shin et al., 2014). Hence there is a need to span beyond probing known TCR signaling 
molecules for their role in Treg-mediated suppression by performing a global and unbiased 
mapping of the dynamics in the phosphoproteome in T cells upon Treg-mediated 
suppression. 
1.11 MS-BASED SUBCELLULAR PROTEOMICS IN T CELLS (BUILDING A 
PROTEOME-WIDE “GPS”) 
Subcellular localization is an important determinant of protein function, since specific 
intracellular compartments can provide favorable niches for specific reactions, protein 
interactions, modifications and stability (Lundberg and Borner, 2019). Deregulation of 
subcellular localization has been implicated in several disorders like cancer, 
neurodegeneration, obesity, genetical and protein misfolding diseases (Hunter, 2012; Kau et 
al., 2004; Luheshi et al., 2008; Wang et al., 2016). Hence the determination of precise 
subcellular location/s can be invaluable in understanding a protein’s biological function and 
devising therapeutic interventions. While the determination of subcellular location by tagged 
proteins (Huh et al., 2003) and antibody-based detection have been successful for targeted 
approaches (Thul et al., 2017), MS-based proteomics methods can provide high coverage and 
generate unbiased proteome-wide subcellular location data. For example, recent 
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advancements in MS techniques have led to the curation of high-resolution maps of the 
subcellular proteome in human cell lines (Itzhak et al., 2016; Orre et al., 2019), human 
fibroblasts (Jean Beltran et al., 2016), murine pluripotent stems cells (Christoforou et al., 
2016), rat tissues (Jadot et al., 2017) and yeast (Nightingale et al., 2019). Although these 
studies have immensely improved the general classification of the subcellular proteome, there 
is a lack of context-specific classification of the subcellular proteome for primary human 
immune cells like lymphocytes. Present efforts to classify the subcellular proteome of CD4+ 
T cells are mainly limited to subtractive approaches of profiling only a particular fraction of 
interest (Filén et al., 2005; Graessel et al., 2015; Moltu, 2013; Moulder et al., 2010; 
Procaccini et al., 2016) or have rather low coverage of the global proteome (Solstad et al., 
2011). High-resolution, global mapping of the subcellular location of the T cell proteome 
would decrease the dependence on subcellular data from unrelated cellular sources and hence, 
could guide a more specific and targeted validation for the spatial information of the protein 
of interest for T cell-specific works.
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2 AIMS 
 
1. To elucidate the molecular mechanisms behind rapid suppression of T cells by Tregs 
(Paper I & II) 
a. To map the global effect on the phosphoproteome of T cells upon suppression 
by Tregs (Paper I) 
b. To study the role of phosphatase inhibitor PPP1R11 in modulation of the 
resistance of T cells against Treg-mediated suppression (Paper II) 
2. To elucidate the mechanism and role of macrophages in the generation of iTregs 
(Paper III) 
3. To map the subcellular proteome and proteome-wide stimulation-induced subcellular 
translocation in T cells (Paper IV) 
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3 METHODS SUMMARY 
To achieve the aims described above, several different methods were employed. Below 
follows a summary of the main methods. Of note, for a more detailed description please refer 
to the individual articles.  
3.1 T CELL:TREG COCULTURE SYSTEM AND STIMULATION 
In order to facilitate the study of rapid signaling upon short term T cell:Treg coculture, we 
used a previously optimized allo-disparate coculture system using cells magnetically isolated 
from human peripheral blood (Schmidt et al., 2011). In short, freshly isolated and HLA-A2 
disparate T cells (CD4+CD25-) were cocultured with pre-activated Tregs (CD4+CD25++; 
O.N. anti-CD3 stimulation) or control T cells for 85 mins and then stimulated for 5 mins with 
cross-linked anti-CD3/anti-CD28 antibodies (referred to as TCR stimulation) for 
phosphoproteomic and phospho-Western Blot studies and 3-5 hours for transcriptomic 
studies such as cytokine mRNA analysis (Paper I). Following quick magnetic separation 
based on HLA-A2 expression, the target T cells were processed for further downstream 
analysis. Alternatively, for long-term stimulation, responder T cells were labeled with CFSE 
and stimulated alone or with Tregs for 3-5 days and proliferation was measured by flow 
cytometry (Paper II). For iTreg generation, naïve CD4+CD25-CD45RA+ T cells were 
cultured with supernatants of macrophages such as M2 macrophages, or TGF-β1 + IL-2 as a 
control (Paper III). Specific details regarding HLA-A2 disparity, pre-activation for Tregs, 
nature and time point of stimulations and cocultures are specifically given in each publication 
(Paper I – IV). 
3.2 MS-BASED PHOSPHOPROTEOMICS 
Apart from the technological limitations, the main constraint of performing 
phosphoproteomics is the required amount of starting material. Utilizing comparatively low 
amount of starting materials (57-196 µg protein per sample) we have been able to perform 
global phosphoproteomics. In brief, trypsin-digested peptides from suppressed T cells, 
stimulated T cells and resting T cells isolated from T cell-Treg, T cell-T cell cocultures and 
untreated T cells (N = 3 donors) respectively were individually labeled with stable isotope 
dimethyl labeling (Boersema et al., 2009) and mixed to enable multiplexing. Phosphopeptide 
enrichment was carried on Titanium ion immobilized metal affinity chromatography (IMAC) 
(Zhou et al., 2013) before processing in the LC-MS. The analyses were based on relative 
quantification of the dimethyl ratios (Paper I).  
3.3 NUCLEOFECTION OF UNSTIMULATED T CELLS 
Nucleofection of plasmids and siRNAs (Paper I & II) were conducted by Neon transfection 
system and Amaxa technology respectively, with several optimizations. The possibility of 
optimizing transfection conditions and voltages enables Neon transfection to be suitable for 
transfection of plasmids (1 kbp) with considerably good viability while transfection with 
Amaxa technology yielded higher efficiency of transfection albeit with compromised cellular 
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viability. Although these methods provide a relatively economical and possibly less labor-
intensive (once optimized) alternatives to study the biological effect of genetic perturbations 
in cellular contexts, they come with their limitations. Of note is that we observed 
electroporation in general affects cellular physiology with elevation in calcium signaling and 
other activation-associated signaling molecules including cellular responses to stimulation. 
Although these effects can be normalized with the use of empty vector or control siRNA, 
caution needs to be administered while resolving differences which are small in magnitude. 
DEF6 plasmids (phospho-mutants, wild type or empty vectors) were transfected in primary 
human T cells. The cells were rested for 8 hours and then stimulated with 5 minutes or 3 
hours of TCR stimulation for Western Blot and mRNA studies (Paper I). For siRNA studies, 
silencing with PPP1R11 and control siRNAs were performed by incubation at 37°C for 4.5 
days (Paper II). In general, cells were stimulated with crosslinked TCR stimulation for 3-6 
hours (RNA studies) or 4.5 days with plate-bound anti-CD3 and soluble anti-CD28 
stimulation (protein studies), or as described for specific experiments. 
3.4 SUBCELLULAR FRACTIONATION AND MS-BASED PROTEOMICS 
The subcellular fractionation strategy was mainly aimed at enabling robust isolation of basic 
cellular meta-components from limited starting materials (20 Million T cells; at least 48 µg 
protein per fraction) suitable for clinical and biological samples of a rare nature. Qproteome 
Cell Compartment Kit was used to isolate cytosolic, nuclear and membrane fractions from T 
cells upon steady state and following 15 or 60 minutes of TCR stimulation. It needs to be 
mentioned that the membrane fraction consists of the plasma membrane as well as the 
membranous organelles. Enzymatically digested peptides were labeled with 10 plex Tandem 
mass tag (TMT) labeling. The multiplex mixtures were pre-fractionated by immobilized pH 
gradient (IPG)-isoelectric focusing on pH 3-10 IPG strips using the high-resolution isoelectric 
focusing (HiRIEF) method (Branca et al., 2014). Peptides were extracted from the gel strips 
into 72 separate fractions which were analyzed by LC-MS/MS. Downstream analyses were 
based on the relative ratios of the individual TMT intensities (Paper IV).  
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4 RESULTS AND DISCUSSION 
4.1 MOLECULAR MECHANISMS OF RAPID SUPPRESSION OF T CELLS BY 
TREGS (PAPER I) 
A series of work by Oberle et al. and Schmidt et al. (Oberle et al., 2007b; Schmidt et al., 
2011) have contributed to the process of understanding the mechanism and signaling in target 
T cells during Treg-mediated direct and rapid suppression of T cells by Tregs. The most 
upstream effect of Tregs was shown to be the inhibition of depletion of intracellular calcium 
stores and suppression of downstream pathways like NFAT and NF-κB in T cells. Despite 
“kick-starting” the discovery of the involved molecules, targeted studies including and 
similar to these studies (Chellappa et al., 2015; Huang et al., 2012; Shin et al., 2014) paint an 
ultra-canonical and yet incomplete view of this process. To understand the global effect of 
Treg-mediated suppression on T cells, we decided to pursue an unbiased strategy by 
comprehensibly mapping the phosphoproteome of T cells upon suppression. Owing to the 
rapid nature of suppression (starting as soon as after 30 mins of T cell:Treg contact and 
detectable with 5 mins of TCR stimulation) and the heavy involvement of phosphorylations 
in regulating TCR signaling we postulated that Tregs suppress T cells by regulating the 
phosphoproteome of T cells. 
4.1.1 Tregs revert the activation-induced phosphorylation in T cells 
5 minutes of TCR stimulation with or without the presence of Tregs produced a massive 
alteration in the T cell phosphoproteome (42% and 19% of total detected phosphopeptides 
changing over 25% upon stimulation and suppression respectively). TCR stimulation mainly 
induced elevation of phosphorylation (397 out of 431 regulated phosphopeptides) and 
strikingly Tregs seemed to reverse the activation-induced phosphorylated state with the 
majority of phosphopeptides exhibiting reduced phosphorylation compared to stimulation 
without Tregs (158 out of 198 regulated phosphopeptides). Further analysis with a statistical 
cutoff of P < 0.05 confirmed that most of these phosphopeptides with reduced 
phosphorylation upon suppression exhibited increased phosphorylation upon activation. This 
is the first indication that Tregs suppress T cells by globally altering the phosphoproteome of 
the target T cells. 
4.1.2 Tregs suppress DEF6 phosphorylation in T cells 
Analyses of phosphoproteins regulated by TCR stimulation and / or by Tregs have unmasked 
several novel candidates, the majority of which are not previously known to be involved in 
TCR signaling, supporting the strength of our unbiased approach. Hence these 
phosphorylations hold potential to unravel novel events in Treg-mediated suppression of 
T cells which are poorly understood so far. These candidates exhibit significant enrichment in 
cytoskeletal remodeling, which is one of the proximal events mediating TCR signaling and 
possibly early signaling events upon T cell and Treg contact. Interestingly, a recent study 
involving phosphoproteomic characterization of murine Tregs and T cells reports a Treg 
specific activation of cytoskeletal regulators (van Ham et al., 2017), although suppressed 
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target T cells were not studied here. Taken together, early signaling events upon T cell and 
Treg contact may be mediated by molecules involved in cytoskeletal remodeling . 
Among the molecules that were differentially phosphorylated by Tregs in our study, a 
lymphocyte-specific guanine nucleotide exchange factor (DEF6 / SLAT) appeared. DEF6 has 
been shown to regulate TCR signaling by IP3R-mediated regulation of Ca2+ / NFAT signaling 
and activation of cytoskeleton-regulating Rho-GTPases (Bécart et al., 2008; Gupta et al., 
2003). Our discovery that Tregs prevent the activation-induced phosphorylation of DEF6 T 
595 and S 597 holds more relevance since these phospho-sites are located in the DH domain 
of DEF6 which is crucial for the activity of DEF6 (Bécart et al., 2008; Cote et al., 2015; Fos 
et al., 2014). Hence, we hypothesized that DEF6 T 595 and S 597 may be involved in 
mediating the functionality of DEF6 in T cell activation and suppression. 
4.1.3 DEF6 T 595 and S 597 phosphorylation contribute to T cell activation 
The initial experiments involved generating mutants of the above-discovered DEF6 phospho-
sites, and transfection of phospho-silent mutants of DEF6 T 595 and S 597 in HEK 293 cells. 
This revealed that these DEF6 phospho-sites mediated the interaction of DEF6 with the IP3R 
which is crucial for the regulation of intracellular calcium levels. Next, we studied the 
functional role of these phosphorylations in shaping the stimulation-induced signaling events 
in primary T cells. Transfection of the phospho-silent mutants of DEF6 led to reduced 
activation of NFAT upon TCR stimulation as compared to wild type DEF6. Similarly, T cells 
overexpressing the phospho-silent mutant DEF6 protein also exhibited lower expression of T 
cell activation-induced cytokines like IL2 and IFNG mRNA; notably, the hallmark cytokines 
to be rapidly suppressed by Tregs. On the other hand, overexpression of the phospho-mimic 
mutants led to enhanced expression of these cytokines as compared to the phospho-silent 
mutants. A similar trend of regulation of other NFAT target genes like IL2RA and FASLG 
was also observed with both the phospho-mutants. Taken together these results suggest that 
these DEF6 phosphorylations positively regulate T cell activation.  
Regulation of T cell activation via interaction with IP3R and NFAT activation by DEF6 may 
be mediated by several domains of DEF6. Membrane translocation of DEF6, mediated by 
domains other than the DH domain (containing T 595 and S 597) seems to be vital for the 
influence of DEF6 on regulation of T cell activation (Bécart et al., 2008; Fos et al., 2014). 
Expression of the DH domain alone has been shown to be insufficient to regulate DEF6:IP3R 
binding unlike other subunits (Fos et al., 2014). However, upon forced membrane 
translocation, the DH domain, alone can completely restore NFAT activation and cytokine 
regulation in murine DEF6 -/- T cells. DEF6:IP3R interaction was not checked in this case 
(Bécart et al., 2008). Taking these observations together with our results, it is highly likely 
that upon proper membrane localization, phosphorylation of DEF6 T 595 and S 597 (in the 
DH domain) regulate the DEF6:IP3R binding and hence stimulation of Ca2+/NFAT signaling 
in T cells. It is feasible that these phospho-sites may distort the overall DEF6 structure to 
hinder the DEF6:IP3R binding, which remains to be further determined. 
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In conclusion, we propose DEF6 T 595 and S 597 phosphorylations to be novel mechanisms 
to regulate T cell activation and Treg-mediated suppression via mediating DEF6:IP3R 
interaction and Ca2+ / NFAT signaling, as depicted in Figure 3. 
Figure 3. Proposed model of 
phosphoproteomic regulation of T 
cell activation and suppression. 
Tregs suppress T cells (red) by 
reverting the activation-induced 
phosphorylation (blue). The 
phosphoproteome of suppressed T 
cells partially resembles resting T 
cells (grey). Tregs suppress T cells 
by inhibiting activation-induced 
phosphorylation of DEF6 T 595 and 
S 597, possibly abrogating 
DEF6:IP3R interaction and 
downstream NFAT signaling and 
cytokine expression. 
  Joshi et al. 2017 Front. Immunol. 
4.2 PPP1R11: A REGULATOR OF T CELL RESISTANCE TO TREGS (PAPER 
II) 
In Paper I, we found that the phosphoproteins regulated by Tregs are functionally enriched in 
cytoskeletal remodeling and we subsequently discovered novel DEF6 phosphorylations 
which regulated T cell activation. When we analyzed the phosphoproteins-regulated by Tregs 
instead for overrepresented protein classes, we observed enrichment of phosphatases, kinases 
and transcription factors. As discussed earlier, TCR signaling is heavily regulated by 
phosphorylations, plus kinases and phosphatases are viable drug targets for clinical 
intervention. Hence, we investigated the phosphoproteomic data for phosphatases and their 
regulators. We observed that Tregs reverted the activation-induced phosphorylation of 
PPP1R11 S 73, S 74, T 75 and S 77 (P = 0.057). PPP1R11 is an inhibitory (regulatory) 
subunit of PP1 phosphatase (Zhang et al., 1998). These 4 phospho-sites constitute most of the 
reported phospho-sites (4 out of 5) in the 12 amino acids long motif of PPP111. Further, this 
motif which houses these phospho-sites, is crucial in maintaining the suppressive effect of 
PPP1R11 on PP1 (Zhang et al., 2008). Since PP1 is the most common of the eukaryotic 
phosphatases, and regulation of PP1 activity is highly dependent on regulatory subunits 
(Bollen et al., 2010), we strived to investigate the relevance of PPP1R11 in shaping the 
response of T cells towards Tregs. We performed siRNA-mediated silencing of PPP1R11 in 
T cells and asked: “Does PPP1R11 affect Treg-mediated suppression?”  
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4.2.1 PPP1R11 modulates resistance to Tregs in T cells 
We utilized an allogeneic T cell:Treg coculture setting with T cells treated with PPP1R11 
siRNA and control siRNA respectively, and subsequently measured the resulting IL-2 and 
IFN-γ levels (mRNA and protein) to analyze the effect of PPP1R11 silencing in shaping the 
T cell response towards activation and Treg-mediated suppression. We observed that Treg-
mediated suppression of stimulation-induced IL-2 and IFN-γ was compromised upon 
PPP1R11 silencing. Further, the extent of abrogation of cytokine suppression was 
proportional and correlated to the efficiency of PPP1R11 silencing in the respective T cells. 
These results show that PPP1R11 regulates resistance of T cells towards Treg-mediated 
suppression. 
4.2.2 PPP1R11 regulates TCR stimulation-induced cytokine expression, and 
PPP1R11 knockdown imparts an activated phenotype to T cells 
While PPP1R11 has been shown to be involved in cell cycle regulation and apoptosis mainly 
by suppression of PP1 in non-immunological settings, the role of PPP1R11 in human 
immunology is not widely studied. We further dissected the direct effect of PPP1R11 on T 
cells in experiments similar to those introduced in the previous paragraph. PPP1R11 silencing 
upregulated the expression of T cell stimulation-induced cytokines like IL-2 and IFN-γ upon 
TCR stimulation (mRNA and protein). Hence, it is plausible that these overactivated T cells 
cannot be sufficiently suppressed by Tregs anymore, as described above. Additionally, 
PPP1R11 silencing also upregulated the TCR-induced expression of CD69, a marker of early 
T cell activation while late activation markers like IL2RA and CTLA4 were not significantly 
affected. Furthermore, PPP1R11 silencing also downregulated PTPN22 (mRNA and protein), 
a phosphatase. Since PTPN22 is reported to negatively regulate the proximal TCR signaling 
(Bottini and Peterson, 2014), affecting PTPN22 might be an additional mechanism how 
PPP1R11 regulates TCR activation, besides its primary target PP1. Some works that have 
already indicated a role of PP1 in TCR stimulation (Thomas Mock, 2012; Wabnitz et al., 
2018) prompted us to follow up on these results, especially in the context of PPP1R11 as a 
novel regulator of T cell activation. It is noteworthy that we observed neither an effect of 
PPP1R11 silencing on PP1A mRNA or protein expression. Our observation is in line with 
earlier works (Bollen et al., 2010; Ceulemans and Bollen, 2004) where it is suggested that 
regulatory subunits instead influence substrate specificity and activity of PP1 by altering its 
subcellular localization and interacting with PP1 substrates. To understand the role of PP1 
itself in T cells and draw comparisons with the effect of PPP1R11 on T cells, we performed 
chemical inhibition of PP1 by tautomycetin (Mitsuhashi et al., 2001), an antifungal agent 
under investigation for usage as an immunosuppressive agent following organ transplantation 
(Wee et al., 2010). PP1 inhibition by tautomycetin suppressed the expression of IL-2 and 
IFN-γ (mRNA and protein). The seemingly reciprocal nature of regulation of the TCR 
activation-associated cytokines between chemical silencing of PP1 and siRNA-mediated 
silencing of PPP1R11 correlatively suggest that PPP1R11 regulates T cell activation via 
repressing its target PP1. In line with our conclusion, PP1A has been indicated as a positive 
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regulator of TCR-induced IL-2 and IFN-γ expression by regulating NF-κB by so far unknown 
mechanism (Thomas Mock, 2012). 
To gain additional understanding of PPP1R11 effects on T cells besides well-known targets 
and TCR signaling regulators, we next performed RNAseq on PPP1R11-silenced T cells in 
the resting stage and upon 6 hours of TCR stimulation to study the potential mechanism and 
global effect of PPP1R11 silencing on the T cell transcriptome. We observed that PPP1R11 
differentially regulated the stimulation-induced expression of several genes which were 
highly enriched in pathways associated with T cell activation. Among this subset of genes 
were surface and proximal mediators of T cell signaling and most of the genes were 
associated with phosphatidylinositol and AKT / MAPK pathways. Furthermore, we also 
observed downstream products of the NF-κB pathway. Our observation indicates that the 
PPP1R11-mediated effect on T cell activation might involve alterations in the MAPK, AKT, 
AP-1 and NF-κB pathways, all of which are reported to be involved in the induction of 
resistance in T cells towards Treg-mediated suppression (Mercadante and Lorenz, 2016; 
Wohlfert and Clark, 2007). However, targeted Western Blot analysis did not exhibit a 
significant difference in the phosphorylated or the total levels of exemplary canonical 
molecules in the MAPK-AP1, NFAT and NF-κB pathways upon PPP1R11 silencing. It 
needs to be considered that regulation may occur via phospho-sites other than the ones we 
have inspected or even by PTMs other than phosphorylation. Further, modulation may also 
be dependent on the time point of activation, all of which were not feasible to be tested by 
targeted studies.  
Taken together, we propose PPP1R11 as a novel negative regulator of T cell activation-
induced cytokine expression and regulator of susceptibility of T cells towards Tregs, as 
depicted in Figure 4. 
Figure 4: Novel role of PPP1R11 in 
the induction of resistance in T cells 
towards immunosuppression by 
Tregs. We propose PPP1R11 to 
modulate Treg-mediated suppression of 
cytokine expression in T cells possibly 
via repression of PP1, which itself 
augments cytokine expression in T 
cells.  
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4.3 UNRAVELING THE EFFECT OF MACROPHAGES IN THE GENERATION 
OF ITREGS (PAPER III) 
In Paper I and II we studied the effect of Tregs on the target T cells, but the differentiation, 
suppressive capacity, and stability of the Tregs themselves are influenced by other immune 
cells (Sakaguchi et al., 2008). Further, the suppressive mechanisms employed by iTregs are 
basically unstudied. In vitro differentiation of iTregs from naïve T cells, mainly by protocols 
involving IL-2 and TGF-β and / or other stimulants have been an excellent option to elucidate 
Treg biology and have also been proposed to be a possible alternative to ex vivo isolated 
Tregs (Lan et al., 2012). However, none of the iTreg-inducing protocols so far has been 
successful in specifically generating TSDR demethylation in the FOXP3 locus, which is one 
of the distinct Treg signatures. Hence the stability and integrity of iTregs are the biggest 
concerns for their clinical application. Conversely, in vivo generated pTregs acquire TSDR 
demethylation in several mouse models (Ohkura et al., 2012; Schmitt and Williams, 2013); 
this suggests that it may be feasible to generate TSDR demethylation and stable iTregs if the 
in vitro induction protocols are optimized to recreate the in vivo generation of pTregs. 
Furthermore, macrophages have been reported to be involved in the generation of Tregs in 
vivo. Recent studies involving the adoptive transfer of tolerogenic macrophages or similar 
cell types in experimental models of autoimmunity have resulted in positive prognosis, 
possibly aided by the generation of iTregs (Haribhai et al., 2016; Weber et al., 2007). Hence 
in Paper III, we studied the feasibility of using supernatants from anti-inflammatory M2 
macrophages generated by using a novel stimulatory protocol (IL-4 / TGF-β / IL-10) (Mia et 
al., 2014; Parsa et al., 2012) in generating human iTregs from naïve T cells. We observed that 
the M2 supernatants could induce iTregs with expression levels of FOXP3 as high as in 
nTregs. These iTregs also expressed high levels of other Treg signature molecules like CD25 
and CTLA-4 with low expression of inflammatory cytokines like IFN-γ. Further, M2-iTregs 
possessed superior suppressive potential regarding in vitro proliferation of responder T cells. 
However, suppression assays with iTregs come with their own complications compared to 
assays with nTregs, one being that the iTreg cells are highly activated and expanded (i.e. not 
anergic) in vitro, hence being able to overgrow responder T cells and suppress unspecifically, 
for example by IL-2 consumption. Therefore, correct controls (like activated T cells 
generated without TGF-β hence not expressing FOXP3) are crucial in such assays, and often 
unspecific yet dose-dependent suppression by non-Tregs is indeed observed (Schmidt et al., 
2016). Studying the differences and similarities in Treg suppression mechanisms between 
iTregs and nTregs is therefore intricate. Although it would be interesting to study whether 
iTregs suppress by similar mechanisms like nTregs regarding DEF6 and PPP1R11, 
preliminary experiments on the suppression of IL2 and IFNG mRNA in Tcons by iTregs 
were inconclusive, perhaps due to the problems associated with the highly activated state of 
iTregs and control T cells as mentioned above (Angelika Schmidt, unpublished data). 
Therefore, we could not further follow up on the mechanistic aspects of iTreg-mediated 
suppression.  
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FOXP3 induction in the iTregs was found to be mediated by TGF-β, initially used to generate 
M2 macrophages. Despite extreme washing and complete removal of soluble TGF-β, 
macrophages captured and rereleased active TGF-β which largely mediated the iTreg 
differentiation. Interestingly, knocking down TGFB expression in macrophages and hence 
blocking new TGF-β expression showed no significant effect on the secreted levels of active 
TGF-β or FOXP3 levels in the iTregs, confirming that initially added TGF-β conferred the 
effects. Notably, none of the iTreg populations we tested acquired TSDR demethylation as 
displayed by nTregs, and consequently, FOXP3 expression was not stable upon 
restimulation. However, M2-induced macrophages exhibited somewhat more stable FOXP3 
expression than iTregs which were generated with IL-2 and TGF-β directly, despite the 
importance of TGF-β in the generation of iTregs by M2 supernatants. In addition, M2-
induced iTregs exhibited superior IFN-γ repression compared to TGF-β-induced iTregs. 
These observations highlight the importance of additional unknown factors besides TGF-β in 
the M2 macrophage-driven iTreg generation. Taken together, instead of in vitro generation of 
iTregs that come with concerns, M2 macrophage transfer may be a more viable option to 
induce Tregs for therapeutic purposes in vivo, which should be further explored in the future.  
4.4 MAPPING THE SUBCELLULAR PROTEOME AND SUBCELLULAR 
PROTEIN TRANSLOCATION IN T CELLS (PAPER IV) 
Paper I and II helped us to appreciate how “looking beyond” the well-known molecules can 
give us novel perspectives in biological pathways like T cell activation and Treg-mediated 
suppression. Since phosphorylation and other PTMs are reported to regulate subcellular 
localization of proteins, we were excited by the idea of mapping the spatial proteome of T 
cells. As discussed earlier, shuttling of several critical elements of TCR signaling across 
subcellular compartments play key roles in T cell activation, so we decided to map the 
proteome-wide subcellular translocation upon TCR activation.   
4.4.1 TcellSubC: an atlas of the subcellular proteome of T cells  
T cells from three different donors in steady state or stimulated states (15 minutes or 1 hour 
of TCR stimulation) were fractionated into three subcellular components, namely cytosol, 
membranes (including organelles), and nuclei. Using high-resolution fractionation and MS-
based peptide detection, our study identified and allocated subcellular localization for 
proteins corresponding to more than 8,000 genes with more than 7,000 shared between the 
three donors. The three clusters acquired by k means clustering corresponded strongly with 
the gene ontology (GO) classification of cytoplasm, membrane, and nucleus and additionally 
with the comparable subcellular classification generated by SubCellBarCode, a recently 
published high-resolution mapping of the subcellular proteome of 5 different cell lines (Orre 
et al., 2019).  
4.4.2 Stimulation-induced subcellular protein translocation 
By considering the proteins that were simultaneously changing in the opposite direction in 2 
or more compartments with |log2FC|>0.201 upon 60 minutes of TCR stimulation, we were 
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able to identify 210 potentially translocating proteins. The majority of these translocating 
proteins involved the membrane fraction (which also includes organelles). Since GO analysis 
on the translocating proteins exhibited components of oxidative phosphorylation and 
mitochondrial complexes this might hint at the importance of protein shuttling during the 
early metabolic changes initiated upon TCR stimulation. Besides, we also observed several 
important transcription factors that were translocating upon activation like NFKB2, 
NFATC1, NFATC3, STAT3, STAT5A, which are already known to translocate upon TCR 
activation (Busino et al., 2012; Meier et al., 2017; Okamura et al., 2000).  
Since PTMs like phosphorylations are known to regulate the subcellular localization of 
proteins, we integrated our translocating proteins with curated sets of activation-induced 
phosphoproteins in T cells in Paper I and other published data sets (Joshi et al., 2017; Nguyen 
et al., 2015b) including PTMs experimentally verified to regulate subcellular localizations 
(Hornbeck et al., 2019). We identified 21 translocating molecules with associated 
phosphorylations or ubiquitinations, which have strong biological relevance to be studied as 
regulators of subcellular localization in T cells.  
Further, orthogonal verification of subcellular translocation was performed with an image-
based approach which produced reproducible results involving stimulation-induced nuclear 
translocation of complement component 3 while the well-studied nuclear translocation of 
NFATC2 was used as a control. This indicates the robust nature of our findings regarding 
subcellular location and stimulation-induced protein shuttling.  
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5 CONCLUDING REMARKS AND PERSPECTIVES 
(Paper I) We have curated a novel resource describing the phosphoproteomic characterization 
of human T cells under resting, stimulated and suppressed states. Our data indicate that Tregs 
suppress T cells mainly by negating the activation induced-phosphorylation of T cells. We 
believe that these phosphoproteins have paved the way for the discovery of novel regulators 
and mechanisms of T cell stimulation and suppression of T cells by Tregs. For instance, we 
have discovered novel roles of DEF6 phosphorylations in regulating the interaction of DEF6 
with IP3R as well as in promoting T cell stimulation via activation of NFAT and transcription 
of activation-induced genes. Our data indicate that Tregs target these DEF6 phosphorylations 
to rapidly suppress T cell activation. However, the specific molecule on the surface of Treg 
and T cells that interact with each other and orchestrate suppression along with the exact 
kinase or phosphatase that regulate DEF6 phosphorylation is still unknown. Further studies 
focusing on the immune synapse formed upon Treg-T cell contact and interaction of several 
phosphorylations in our study are required for a comprehensive understanding of the direct 
suppression pathway. Further, it would be of importance to generate DEF6 phospho-mutants 
in a DEF6 knockout background and study the effects on T cell activation and Treg 
suppression, also in disease models, to further understand the importance of DEF6 
phosphorylation in vivo.  
It is to be considered that the phospho-regulation of contact-dependent rapid suppression is 
one among various mechanisms of suppression which vary depending on the immune micro 
milieu and possibly the subsets of both T cells and Tregs. The direct regulation of T cells by 
Tregs is more likely to be relevant in the inflamed tissue to control the inflammation and 
probably serve as an additional mechanism to implement peripheral tolerance when the 
suppression of classical DC-mediated priming of T cells in the lymph nodes fail or is 
insufficient. 
(Paper II) By following up on candidates from our phosphoproteomic screen, we have 
identified the role of phosphatase inhibitor PPP1R11 in inducing resistance towards Tregs in 
T cells, and as a novel negative regulator of TCR activation-induced cytokine expression. The 
underlying molecular mechanisms mediating the effect of PPP1R11 in T cells is still unclear. 
However, our data indicate that PPP1R11 affect T cell signaling by inhibiting PP1 
phosphatase possibly via regulating the substrate specificity, activity of PP1 or competing 
with PP1 substrate rather than direct transcriptional or translational regulation of PP1. Our 
data also point at the possible involvement of AP-1 and NF-κΒ pathways while the 
identification of the exact molecule/s and mode of regulation still remains elusive. Since the 
efficiency of siRNA-based transient silencing of PPP1R11 dilutes with each cell division, 
future follow-up studies with stable PPP1R11 knockout as well as phospho-mutants in 
cellular and animal models are required to elucidate the exact molecular mechanism and in 
vivo relevance.  
Discovery of PPP1R11 as a regulator of T cell resistance and a potential role of PTPN22 
phosphatase in mediating part of the effects of PPP1R11 from our study and reports of SHP-1 
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phosphatase being involved in T cell resistance from another study (Mercadante and Lorenz, 
2017) support the possibility of using phosphatase-modulating drugs in the therapeutic 
intervention of T cell resistance. Although the PP1 inhibiting drug Tautomycetin is presently 
available, targeting a ubiquitous and multi-functional phosphatase, which may even have 
opposing functions in different cell types (Gu et al., 2014; Thomas Mock, 2012), needs to be 
done in a cautious and cell type-specific manner. Instead of targeting the catalytic core of PP1 
as done for kinases, it might be more specific to target regulatory subunits like PPP1R11 
which have been reported to control the substrate specificity and activity of the phosphatase 
and even its cell-type specific function (Bollen et al., 2010). 
The biological significance of PPP1R11, DEF6, and our phosphoproteomic database provide 
novel targets and avenues to revisit the role of T cells in immunotherapy, especially to 
modulate the sensitivity of T cells towards suppression of T cells by Tregs. Interesting 
clinically relevant and open questions remain to be explored: 
1. Can the candidate molecules from our phosphoproteomic study be used to predict 
disease prognosis or therapy outcome for ongoing clinical trials involving Tregs? 
2. Can the candidate molecules be targeted to regulate the T cell susceptibility to Tregs 
in disease situations?  
(Paper III) By shifting our focus to the generation of iTregs, we discovered the ability of M2 
macrophages in generating human iTregs mainly by capturing and re-releasing TGF-β, 
primarily used in the differentiation of M2 macrophages themselves. The superior stability 
and suppressive capabilities of M2-iTregs over TGF-β-iTregs may be accredited to additional 
factors produced by M2 macrophages which are yet to be identified. We provide a novel 
protocol for in vitro generation of iTreg using M2 macrophages induced by TGF-β-
containing optimized cytokine cocktail. In contrast to the systemic delivery of TGF-β, 
adoptive transfer of M2 macrophages might be a more specific and effective alternative for 
targeted delivery of TGF-β and restoration of immune suppression possibly via Treg 
induction. Whether this scenario could be exploited in vivo, and which molecular 
mechanisms of suppression are employed by iTregs, remain to be investigated.  
(Paper IV) We have curated a high-resolution subcellular proteomic map of primary human T 
cells, divided into cytosolic, nuclear and membrane (including organelles) fractions under 
steady-state conditions and upon 15 minutes and 1 hour of T cell receptor (TCR) stimulation 
respectively. The subcellular classification is presently based on clustering analysis and can 
certainly be improved by applying machine learning aided subcellular classification in the 
future as done in other studies (Christoforou et al., 2016; Orre et al., 2019). Our database will 
particularly support functional studies of the novel molecules identified from several global 
omics and prediction studies which are getting more and more common with the advent of 
high throughput technologies. The subcellular location from our study can be readily used as 
a basis for hypothesis generation for T cell-specific cellular function of proteins, as well as 
for studies exploring the importance of these localizations in Treg-mediated suppression of T 
cells. 
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Mapping the spatial proteome by targeted experiments, tagged proteins and antibody-based 
imaging approaches like Human Cell Atlas (Huh et al., 2003; Thul et al., 2017) and global 
MS-based studies (Christoforou et al., 2016; Itzhak et al., 2016; Jadot et al., 2017; Jean 
Beltran et al., 2016; Nightingale et al., 2019; Orre et al., 2019) including our present study 
have contributed an immense amount of data involving subcellular localization of proteins in 
different cells and contexts. The next challenge of the field is to integrate the data for meta-
analysis of subcellular proteome acquired from several of these approaches and make it more 
accessible via a user-friendly interface. Ultimately, it would be of great interest to study 
subcellular protein translocations globally also in T cells upon suppression by Tregs. 
However, the amount of starting material required despite highly sensitive proteomics 
methods employed so far, precluded us from performing these studies with Treg-suppressed 
T cells as well.  
In conclusion, with these novel phosphoproteomic and subcellular proteomic data in T cells 
and transcriptomic data on resistant T cells, we set the stage for further studies employing 
targeted analysis of the relevance of these novel findings in TCR activation and Treg-
mediated suppression. Our data contribute to understanding and revisiting the role of T cells 
in basic biology and disease, and ultimately, to develop better therapeutic strategies for 
autoimmune diseases, allergies and cancer.  
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